To our knowledge, this is the very first study that explores the anticancer potential of BRD4 PROTAC and PTEN plasmid loaded lipid nanocarriers based combinatorial approach to target c-Myc expression inhibition and provides a promising therapeutic option for drug-resistant melanoma, for which there are no effective treatments at present. The gene discussed is BRD4; the disease is melanoma.